Rheumatology Network's Top 5: April 23, 2021

In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.

In phase 1 COMPARE, 4 of 6 patients with refractory RA achieved remission by week 36 following CD19 CAR T-cell therapy.

ACR 2026 data show 56.7% of patients with PsA met GLP-1 RA eligibility criteria, but only 15.7% were prescribed treatment.

Once-weekly retatrutide reduced WOMAC pain and body weight vs placebo in two phase 3 trials, with up to 69.6% of participants halving knee pain at week 68.

Two ACR Convergence 2026 studies tie GLP-1 receptor agonists to lower cardiovascular and mortality risk.

Two ACR 2026 abstracts report rising cardiovascular deaths in Sjögren syndrome and superior ESSDAI response with baricitinib vs hydroxychloroquine.

Kate Harnden, MBChB, PhD, discusses models predicting persistent arthritis after checkpoint inhibitor therapy, presented at EULAR 2026 and as an ACR plenary.

Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.